OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at the 2021 American Society of Clinical Oncology ...


NICOLAS is the first completed single-arm phase II trial in stage III non-small-cell lung cancer ( NSCLC ) examining hierarchically first the safety and then the efficacy of adding Nivolumab ( Opdivo ...


Consolidation Durvalumab after chemoradiation ( CRT ) is the current standard of care for locally advanced non-small-cell lung cancer ( NSCLC ). Researchers have hypothesized that adding immunothe ...


Non-small-cell lung cancer ( NSCLC ) is terminal in most patients with locally advanced stage disease. Researchers have assessed the antitumour activity and safety of neoadjuvant chemoimmunotherapy ...


Sintilimab ( Tyvyt ), an anti–programmed death 1 antibody, plus Pemetrexed and Platinum had revealed promising efficacy for nonsquamous non-small-cell lung cancer ( NSCLC ) in a phase 1b study. Re ...


Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status in patients with advanced ALK immunohistochemistry ( ...


In the randomized KEYNOTE-407 study, Pembrolizumab ( Keytruda ) plus Carboplatin and Paclitaxel / nab-Paclitaxel ( chemotherapy ) has significantly improved overall survival ( OS ) and progression-fre ...


Osimertinib ( Tagrisso ) is standard-of-care therapy for previously untreated epidermal growth factor receptor ( EGFR ) mutation–positive advanced non–small-cell lung cancer ( NSCLC ). The efficacy ...


The efficacy and safety of the anti–programmed death ligand 1 ( PD-L1 ) monoclonal antibody Atezolizumab ( Tecentriq ), as compared with those of Platinum-based chemotherapy, as first-line treatment ...


Five-year survival results from the pivotal phase 3 KEYNOTE-024 trial were presented at ESMO Virtual Congress 2020. Sustained, long-term survival benefit and durable responses with Pembrolizumab ( ...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib ( Xalkori ) in treatment-naive ALK-positive non-small-cell lung c ...


According to phase II trial PRINCEPS, no safety signals were raised, no major toxicity and no surgery impairment were reported following one cycle of neoadjuvant Atezolizumab ( Tecentriq ) therapy in ...


Entrectinib ( Rozlytrek ) is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor ( TKI ). In a preliminary analysis ( data cut-off: 31 May 2018 ) of patients with ROS1 fusion-positive ( ...


Pembrolizumab ( Keytruda ) plus Olaparib ( Lynparza ) has shown antitumor activity and acceptable safety in Docetaxel-pretreated pts with metastatic castration-resistant prostate cancer ( mCRPC ) enro ...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake research to identify biomarkers of response and resis ...